Fifty nine patients with Helicobacter pylon positive duodenal ulcers that failed to heal after a six week course of treatment with H2 blockers were randomly assigned to one of the following three regimens: (i) bismuth subsalicylate, 600 mg three times daily (n=19), (ii) ranitidine, 300 mg at night (n=20), (iii) bismuth subsalicylate plus ranitidine (n=20). Cumula 
H pylon after four weeks were: bismuth subsubsalicylate 58%, ranitidine 0%, bismuth subsalicylate plus ranitidine 55%. After stopping bismuth therapy bacterial recrudescence frequently occurred. After bismuth treatment 86% (19/22) of ulcers had healed ifHpylori had been cleared, whereas only 65% (11/17) had healed if H pylon persisted (NS). This study shows that bismuth subsalicylate is more effective in the treatment of resistant duodenal ulcers than standard dose ranitidine. It may be that suppression of H pylori by bismuth subsalicylate promotes ulcer healing.
Approximately 85-95% of duodenal ulcers heal within six to eight weeks of treatment with standard doses of H2 blockers.'2 The reasons for treatment failure remain unclear but inadequate control of acid secretion may be a crucial factor.'3 Recently, the identification of Helicobacter pyloni and its association with duodenal ulcer disease led to the hypothesis that H pylon might be involved in H2 blocker resistant ulceration. 2 The successful treatment of H2 blocker refractory ulcers by colloidal bismuth subcitrate, which is able to eliminate H pylon, supports this theory.45 Unfortunately, the role of H pylon was not investigated in these therapeutic trials. Bismuth salts exert At initial endoscopy the ulcer size was assessed and antral biopsy specimens were taken for histological examination and H pylori screening. All patients were H pylori positive. Detailed information on duration and age of onset of dyspeptic symptoms, previous drug therapy, previous ulcer complications, and social habits were recorded.
After giving informed verbal consent, patients were randomised by a nurse (to guarantee blindness of the investigators) using given regimens stratified for 63 subjects. Randomisation procedure was accomplished by a computer program. Patients were allocated to receive one of the following three treatment regimens: (i) bismuth subsalicylate (Jatrox) 600 mg three times daily (two chewable tablets half an hour before the three meals); (ii) ranitidine (Zantac) 300 mg at night; (iii) Cimetidine 800 mg/day (n) 14 12 16 Ranitidine 300 mg/day (n) 5 8 4 BBS= bismuth subsalicylate. In the biopsy specimens of the antrum taken before entry active chronic gastritis was found to a similar extent in all study groups (Fig 3) . Gastritis scores fell after four weeks of bismuth subsalicylate and were still somewhat lower at eight weeks in these patients when compared with basal values. In parallel to the H pylon scores, ranitidine monotherapy failed to improve gastric inflammation at any time. Bismuth treatment reduced the density of bacterial colonisation of the gastric mucosa, but there was only a transient clearance of H pylon. Stopping treatment was frequently associated with a recurrence of the organism in the gastric mucosa showing that eradication of H pylon is a rare event during bismuth treatment. In agreement with previous studies,'7" 1 we found a close relation between the grade of chronic gastritis and the degree of infestation of gastric mucosa with H pylon. A reduction in the H pylon score was associated with an improvement in gastric inflammation. Therefore, the difference in ulcer healing rates in patients treated with bismuth v those treated with ranitidine may be partly a result of an improvement of histology.
The role of H pylon in acute ulcer healing seems to be of less importance than its role in the recurrence of duodenal ulcers. A growing body of evidence has accumulated indicating that eradication of H pylori is associated with a significant reduction in ulcer relapses and may even cure duodenal ulcer disease. 5 16 19 The causes of H2 blocker ineffectiveness in acute ulcer healing have not been fully clarified. Inadequate acid suppression has been frequently observed in H2 antagonist non-responders.2"23 In addition, almost all H2 blocker resistant duodenal ulcers can be healed by the potent proton pump inhibitor omeprazole.2425 Therefore, inadequate control of acid secretion by H2 blockers seems to be the most important factor in treatment failures.
In conclusion, our study shows that bismuth subsalicylate is effective in the treatment of H2 blocker resistant duodenal ulcers. In addition, bismuth subsalicylate is superior to a prolonged administration of standard dose H2 antagonists. The beneficial effects of bismuth subsalicylate in the treatment of resistant ulcers may result from suppression of H pylon and the associated improvement of gastritis in addition to its well known cytoprotective properties
